ZYME vs VERA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZYME · Zymeworks$26.14 ▼ 2.68%
VERA · Vera Therapeutics$25.45 ▼ 4.86%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZYME +4.6%
- VERA -13.0%
Head to head
| Metric | ZYME | VERA |
|---|---|---|
| Price | $26.14 | $25.45 |
| Change today | ▼ 2.68% | ▼ 4.86% |
| Market cap | $1.81B | $1.84B |
| Return, 3 months | -9.1% | -24.5% |
| Return, year to date | -0.7% | -49.7% |
| Return, 1 year | +8.8% | -10.6% |
| P/E (TTM) | 49.3 | – |
| P/B | 7.0 | 5.5 |
| P/E percentile vs own 5y | 100th | 78th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +828.7% | – |
| Net profit growth (YoY) | +986.1% | -16.7% |
| Gross margin | – | 67.9% |
| Operating margin | 16.6% | -4,160.1% |
| Net margin | 16.3% | -4,041.2% |
| Return on equity | 15.0% | -113.5% |
| Analyst target vs. price | +60.0% | +175.8% |
| Analyst buy share | 100% | 83% |
| RSI (14) | 43 | 36 |
| 30-day volatility | 56.5% | 62.4% |
| Max drawdown, 1 year | -23.6% | -54.3% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VERA is the largest of the group by market value.
- ZYME has returned the most over the past year.
- ZYME keeps the most profit per dollar of sales.
- ZYME has been the calmest stock over the last 30 days.